GLP-1 in Mexico: physician-supervised semaglutide and tirzepatide
A physician-led weight management and metabolic health program using GLP-1 receptor agonists, at a real Cancún clinic with a COFEPRIS license. Evaluation, lab work, titration and follow-up, with no shortcuts.
What GLP-1 receptor agonists are
GLP-1 receptor agonists are molecules that mimic glucagon-like peptide-1 (GLP-1), an incretin hormone your gut releases naturally after eating. GLP-1 regulates appetite in the brain, slows stomach emptying and improves the insulin response. By harnessing those mechanisms, drugs such as semaglutide and tirzepatide have become first-line tools for weight management and metabolic health when used inside a medical program.
At Regeneris we integrate them into a clinical approach that begins with a medical evaluation, lab work and a personalized titration and follow-up plan. We do not offer them as a standalone product: they are part of an accompaniment that combines nutrition, physical activity and medical monitoring so results are safe and sustainable. You can read the dedicated semaglutide page or return to the peptides program for the full picture.
How they work
- 1Regulate appetite centrally: they mimic the incretin GLP-1, which acts on the hypothalamus and reward centers to reduce hunger and cravings.
- 2Slow gastric emptying: they prolong the feeling of fullness after meals, helping you naturally reduce portion sizes.
- 3Improve insulin sensitivity: they enhance glucose-dependent insulin secretion and lower glucagon, supporting glycemic control.
- 4Tirzepatide adds GIP activity: this dual GIP/GLP-1 mechanism can broaden the effect on appetite and on glucose and lipid metabolism.
Semaglutide vs. tirzepatide: which one fits?
Semaglutide is a single-receptor agonist (GLP-1). Tirzepatide is a dual agonist: it acts on the GLP-1 receptor and also on GIP, another incretin hormone. That dual mechanism can translate into an added effect on appetite and on glucose and lipid metabolism in some people. Both are given as a once-weekly subcutaneous injection.
Semaglutide (GLP-1)
- Single-receptor agonist (GLP-1)
- Extensive clinical experience for weight management
- Once-weekly subcutaneous injection
- Often a sound starting point depending on the case
Tirzepatide (GIP/GLP-1)
- Dual agonist (GIP + GLP-1)
- Dual mechanism on appetite and metabolism
- Once-weekly subcutaneous injection
- An option when the physician seeks an added effect
Choosing between the two molecules is an individualized clinical decision the physician makes with you based on your history, your goals and your tolerance. It is not a self-service decision.
Benefits when used properly
- Clinically meaningful, sustained weight loss when paired with nutrition and physical activity
- Reduced appetite, cravings and the “food noise” that drives overeating
- Better glycemic control and improved insulin resistance
- Improvement in metabolic markers (blood pressure, lipid profile, waist circumference)
- Convenient, discreet once-weekly subcutaneous injection
- Continuous medical support to titrate the dose and manage side effects
Who it is for (and who it is not)
May be appropriate if...
- BMI ≥ 30, or BMI ≥ 27 with at least one related comorbidity (prediabetes, hypertension, dyslipidemia, sleep apnea, fatty liver)
- Type 2 diabetes or prediabetes where a physician judges a GLP-1 agonist to be appropriate
- People who have already tried lifestyle changes and need supervised pharmacological support
Not appropriate if...
- Pregnancy, breastfeeding or actively trying to conceive
- Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
- History of pancreatitis or significant gallbladder disease without prior evaluation
- Active eating disorders
- Recreational or cosmetic use without clinical criteria or follow-up
Medical evaluation, lab work and titration
Every GLP-1 program at Regeneris begins with a medical evaluation in which the physician reviews your medical history, your goals and any possible contraindications. When relevant, we request lab work (for example glucose, HbA1c, lipid profile, kidney and liver function) to get a metabolic snapshot of your starting point.
The dose starts low and is increased gradually (titration) over the first weeks, which improves tolerance and reduces side effects. Follow-up is closer at the start and then periodic, to adjust the dose, monitor response and manage any discomfort. This accompaniment is what separates a medical treatment from buying a molecule online.
Safety, side effects and supervision
Protocol supervised by Dra. Marian Tufano
Professional license (cédula) 12353680, verifiable with SEP
- COFEPRIS-regulated clinic. Molecules sourced through licensed pharmacy channels, not the grey market.
- Used under medical prescription, with prior evaluation, titration and documented follow-up.
- Semaglutide and tirzepatide are molecules backed by large clinical trials for weight management and type 2 diabetes.
- The most common side effects are gastrointestinal (nausea, constipation, reflux) and are usually mild and transient during titration.
- Gradual dose titration under medical supervision substantially reduces the intensity of side effects.
- Follow-up allows us to monitor response, adjust the dose and catch any adverse event early.
Key contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Acute or chronic pancreatitis
- Pregnancy and breastfeeding
- Known hypersensitivity to the molecule
An important warning: sourcing semaglutide or tirzepatide through unregulated channels or without medical follow-up exposes you to incorrect dosing, products with no quality control and avoidable risks. The difference between a good outcome and a bad experience usually comes down to supervision.
How it fits our regenerative and longevity approach
GLP-1 weight management is one piece of a broader regenerative and longevity approach. Metabolic health influences inflammation, energy and the body's capacity to repair itself, so it is frequently integrated with other protocols in the peptides program. If you want to understand how peptides compare with other regenerative therapies, see our peptides vs. stem cells page. The goal is not just to lose weight, but to improve underlying metabolic health.
Frequently asked questions about GLP-1
Answers about semaglutide, tirzepatide and supervised weight management. For questions about the program in general, visit the general FAQ.
It is a molecule that mimics GLP-1, a natural incretin hormone your gut releases after eating. It acts on the brain to reduce appetite and cravings, and on the digestive tract to slow gastric emptying and prolong fullness. Semaglutide and tirzepatide are the most widely used GLP-1 agonists for weight management and metabolic health.
Semaglutide acts on a single receptor (GLP-1). Tirzepatide is a dual agonist: it acts on GLP-1 and also on GIP, another incretin hormone. That dual mechanism can deliver a stronger effect on appetite and metabolism in some people. Choosing between them depends on your medical history, your goals, your tolerance and the medical evaluation, it is not a self-service decision.
Typical candidates have a BMI ≥ 30, or BMI ≥ 27 with at least one comorbidity (prediabetes, hypertension, dyslipidemia, sleep apnea, fatty liver). The medical evaluation reviews your history, your lab work and your goals before determining whether a GLP-1 agonist is appropriate, and rules out contraindications such as a history of medullary thyroid carcinoma, MEN 2, pancreatitis or pregnancy.
Before starting we usually request basic metabolic labs (glucose, HbA1c, lipid profile, kidney and liver function, depending on the case). The dose starts low and is increased gradually (titration) over the first weeks. Medical follow-up is closer at the start and then periodic, to adjust the dose, monitor response and manage any side effects.
The most common are gastrointestinal: nausea, constipation or reflux, usually mild and transient during titration. Medical supervision matters because it lets us titrate the dose correctly, rule out contraindications, watch for warning signs (such as severe abdominal pain) and give you an exit plan. Sourcing these molecules through unregulated channels or without follow-up exposes you to incorrect dosing, products with no quality control and avoidable risks.
When you stop, some appetite tends to return and weight can be regained if durable habits were not established. That is why the program is built around nutrition, physical activity and a gradual exit protocol, so the results are as sustainable as possible.
First step
Medical evaluation
Personalized plan and quote after your evaluation
Administration
Once-weekly subcutaneous injection
Follow-up
Continuous, per medical evaluation
Prior medical evaluation required.
Take the Next Step
For Your Health Today
Schedule your complimentary medical evaluation and find out whether a molecular optimization program is right for you. At your pace, calm and clear.